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One Sentence Summary: Lung premalignancy and early-stage adenocarcinoma use a mechanism
of glucose transport that can be targeted for early diagnosis and treatment.
Abstract: The diagnostic definition of indeterminate lung nodules as malignant or benign poses a 
major challenge for clinicians. We discovered a potential marker, the sodium glucose transporter 
2 (SGLT2), whose activity identified metabolically active lung premalignancy and early-stage 
lung adenocarcinoma (LADC). We found that SGLT2 is expressed early in lung tumorigenesis 
and is found specifically in pre-malignant lesions and well-differentiated adenocarcinomas. Of 
note, SGLT2 activity could be detected in vivo by positron emission tomography (PET) with the 
tracer methyl-4-[
18
F] fluorodeoxyglucose (Me4FDG), which specifically detects SGLT activity. 
Using a combination of immunohistochemistry and Me4FDG PET, we identified high expression 
and functional activity of SGLT2 in lung premalignancy and early-stage/low-grade LADC. 
Furthermore, selective targeting of SGLT2 with FDA-approved small molecule inhibitors, the 
gliflozins, greatly reduced tumor growth and prolonged survival in autochthonous mouse models
and patient-derived xenografts of LADC. Targeting SGLT2 in lung tumors may intercept lung 
cancer progression at early stages of development by pairing Me4FDG PET imaging with therapy 
using SGLT2 inhibitors.
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. 
Despite the success of targeted and immune-based therapies in NSCLC (1, 2), early diagnosis and 
surgical resection of early-stage disease remain the best opportunity for a cure: the 5-year survival 
of NSCLC patients is 55.6% for localized disease but only 4.5% for metastatic disease (3, 4). 
However, according to statistics of the NIH Surveillance, Epidemiology, and End Result Program, 
only 16% of newly diagnosed lung cancers are localized, whereas the majority has already spread 
to regional lymph nodes or to distant metastatic sites at the time of diagnosis
(seer.cancer.gov/statfacts/html/lungb.html). Recently, intensive research efforts have been 
directed to the elucidation of the molecular mechanisms of pulmonary premalignancy development 
and progression (5-7), to find signatures of premalignancy that can be targeted for early diagnosis 
and cancer chemoprevention/interception (8, 9).
Lung adenocarcinoma (LADC) and squamous cell carcinoma (SqCC) are the most frequent 
histologic subtypes of NSCLC. The sequence of pre-malignant lesions that leads to the 
development of SqCC has been extensively described and studied (10), because SqCC develops
from the respiratory epithelium of large airways that are accessible by bronchoscopy. Conversely, 
LADC develops mostly within terminal bronchioles and alveoli, which are not readily accessible
by bronchoscopy. Therefore, LADC premalignancy has been more elusive; the only pre-malignant 
lesion known to be a precursor of LADC is atypical adenomatous hyperplasia (AAH), consisting 
of a localized growth of pre-malignant, cuboidal cells lining the alveolar walls, defined as a lepidic 
pattern (3, 11-14). AAH can progress to adenocarcinoma in situ (AIS) and minimally invasive 
adenocarcinoma (MIA), both of which are precursors of invasive adenocarcinoma and are also 
characterized by lepidic growth. AAH, AIS, and MIA can be detected in vivo by high-resolution 
computed tomography (CT), typically presenting as pure or predominantly ground-glass nodules 
(GGNs) (15-17). However, CT is not specific, and GGNs can also correspond to benign lesions, 
such as alveolar inflammation and hemorrhage. Thus, biomarkers to aid the diagnostic definition 
of GGNs and to identify AAH, AIS, and MIA non-invasively are urgently needed.
An important hallmark of cancer is the increased requirement of glucose (18, 19). Glucose 
is thought to be imported into tumor cells primarily through specific glucose transporters known 
as GLUTs, which are frequently over-expressed in cancer cells (20-22). Glycolytic metabolism is 
readily imaged in cancer by positron emission tomography (PET) using a glucose analog, 2-[
18
F] 
fluorodeoxyglucose (FDG) (20). Although FDG PET is a standard tool for staging lung cancer, it 
has low sensitivity for identifying premalignant GGNs and early invasive disease (17, 23). The 
absence of FDG uptake in AAH and early-stage LADC has been interpreted as a consequence of 
a slow growth rate and low requirement of glucose (15, 17, 23, 24). However, we previously 
discovered that cancers can take up glucose by using an alternative glucose transport system, the 
sodium-dependent glucose transporters (SGLTs) (25, 26). SGLT-mediated glucose transport is not 
detected by FDG PET because FDG is not a transport substrate for SGLTs and is selective for only 
GLUT transporters (26, 27). 
Here, we present evidence that SGLT2 is a potential marker of pulmonary premalignancy
and early LADC. SGLT-dependent glucose uptake can be selectively measured in vivo by PET 
imaging using the radiotracer methyl-4-[
18
F] fluorodeoxyglucose (Me4FDG). Me4FDG is a PET 
tracer transported specifically by SGLTs, and not by GLUTs. This was demonstrated by in vitro 
studies showing that uptake of FDG can be completely abolished by GLUT inhibitor cytochalasin 
B and is not sensitive to SGLT inhibitor phlorizin (26). Conversely, Me4FDG uptake is completely 
abolished by phlorizin but is not affected by cytochalasin B, suggesting that Me4FDG cannot be 
transported by GLUT (26). In vivo, Me4FDG, unlike FDG, cannot cross the blood-brain barrier, 
because the capillary blood vessels of the blood-brain barrier express GLUTs but not SGLTs (27). 
In human PET scans, we have previously shown that Me4FDG gives no signal in the normal brain, 
but is readily taken up by glioblastomas, which are typically characterized by microvascular 
proliferation, disruption of the blood-brain barrier, and SGLT2 expression (28). We previously 
showed SGLT2 expression in human pancreatic and prostate adenocarcinomas (25). Here, we 
demonstrate that LADCs predominantly use SGLT2 to transport glucose in the early stages of 
carcinogenesis. As tumors progress to advanced, poorly differentiated carcinomas, they up-
regulate GLUT-mediated glucose transport, consistent with frequent positivity for FDG uptake. 
Using Me4FDG PET to image SGLT activity in vivo, we were able to functionally distinguish 
SGLT2-mediated active transport of glucose from GLUT1-mediated facilitative diffusion of 
glucose in genetically engineered mouse models (GEMMs) and in patient-derived xenografts 
(PDXs) of lung cancer. Finally, we showed that SGLT2 may be an effective therapeutic target in 
early-stage LADC in both GEMM and PDX models. Our results indicate that PET-guided imaging 
of SGLT2 activity may offer a means to identify metabolically active pulmonary premalignancy
and early LADC and thus could guide targeted therapy/cancer interception with SGLT2 inhibitors.
Results
SGLT2 is a glucose transporter specifically expressed in lung premalignancy and well-
differentiated cancer
We have previously shown the expression of SGLT2 in human pancreatic and prostate 
adenocarcinomas (25) and in glioblastomas (28). Furthermore, SGLT2 expression has been
observed in metastatic lung cancers (29). To investigate glucose transporter expression in LADC, 
we performed IHC staining for SGLT2 and GLUT1 proteins on 58 human LADC samples (stage 
I-IV) (fig. 1). The specificity of the SGLT2 antibody was confirmed by immunohistochemistry
(IHC) in knockout mouse kidneys lacking the SGLT2 protein and by pre-incubation of the 
antibody with the antigenic peptide (fig. S1A-C). The clinical and pathological features of the 
patients are presented in table S1, along with the quantification of SGLT2 and GLUT1 staining by 
IHC. SGLT2 was highly expressed in well-differentiated (lepidic) and moderately differentiated 
LADC; its expression was reduced in poorly differentiated, solid-growth disease (fig. 1A, upper 
panels). Conversely, GLUT1 expression was low in well-differentiated LADC and progressively 
increased in poorly differentiated tumors (fig. 1A, lower panels). Quantification of the IHC signal 
showed a significant reduction of SGLT2 (p = 0.001) and an increase in GLUT1 (p < 0.001) 
staining as the tumor progressed from lepidic (well differentiated) to moderately and poorly 
differentiated LADC (fig. 1B). We therefore hypothesized that early-stage LADCs rely on SGLT2 
for glucose uptake, whereas more advanced tumors rely on GLUT1. We did not observe a 
significant change in SGLT2 and GLUT1 staining from Stage I to Stage IV cancers (fig. S1D), but
samples from stage IA patients had significantly higher expression of SGLT2 (p = 0.04) and lower 
expression of GLUT1 (p = 0.02) than samples from all other stages (fig. S1E). This prompted us 
to hypothesize that SGLT2 expression is an early event in lung cancer development. We
investigated SGLT2 and GLUT1 expression in premalignant lung lesions observed in 9 of the 58 
patients, whose clinical characteristics are reported in Table 1. In most patients, multiple GGNs 
were discovered incidentally on CT performed for other reasons, on screening CT, or as 
synchronous lesions at the time of resection of an invasive LADC (Table 1). We performed IHC
on 11 AAH lesions, 3 AIS lesions, and 3 MIA lesions. SGLT2 was not expressed in normal lung 
alveoli (fig. 1C, upper panel), but was up-regulated in premalignant lesions (fig. 1D, upper panels). 
GLUT1 expression was absent in normal alveoli and premalignant lesions (fig. 1C-D, lower 
panels).
The pattern of IHC staining with SGLT2 in low-grade and GLUT1 in high-grade LADC was 
confirmed in four patient-derived xenografts (PDXs). PDX #004 was characterized as a 
predominantly well-differentiated LADC that expressed high SGLT2 and had no GLUT1 
expression (fig. 1E, left panels). In PDX #011 and PDX #186, the predominant histology was 
moderately differentiated LADC that expressed both SGLT2 and GLUT1 (fig. 1E, central panels). 
Lastly, PDX #013 was characterized as predominantly poorly differentiated LADC that was 
positive for GLUT1 but negative for SGLT2 (fig. 1E, right panels). Together, these data suggested 
that SGLT2 is predominantly expressed in human premalignancy and early-stage, well-
differentiated LADCs, and as lung tumors progress to advanced and poorly differentiated cancers,
they upregulate GLUT1 as the dominant transporter.
PET imaging reveals differential activity of SGLT2 and GLUT1 transporters in LADC 
We have previously profiled functional expression of SGLT2 in mouse xenografts of pancreatic, 
prostate, and brain tumors and have shown that PET imaging with FDG alone fails to 
comprehensively profile glucose uptake in tumors that express SGLT2 (25, 28). To study the 
functional activity of SGLTs in LADC, we used a conditionally activated Lox-Stop-Lox Kras
G12D
, 
p53
lox/lox
, Rosa26-Lox-Stop-Lox-Luc (referred to as KPluc) genetically engineered murine model 
(GEMM), in which tumor induction with adenovirus expressing Cre recombinase simultaneously 
activates oncogenic Kras
G12D
, deletes p53, and induces activation of a luciferase reporter enabling 
bioluminescent imaging of tumors (30). In this model, LADCs are induced by inhalation of 
adenovirus encoding for Cre recombinase. To estimate the activity of GLUTs and SGLTs in 
LADC, we performed PET imaging with FDG and Me4FDG in KPluc mice with advanced stage 
tumors. The same mice were imaged with both tracers on different days. We observed a modest, 
but significant correlation between FDG and Me4FDG uptake in lung tumors (r = 0.4966, p < 
0.0001), suggesting that advanced carcinomas may use both SGLT2 and GLUT1 for glucose 
transport (fig. 2A). A closer observation identified a subpopulation of smaller Me4FDG-positive
lesions in KPluc mice that were negative for FDG uptake (red box in fig. 2A). Figure 2B shows 
representative PET/CT scans of a mouse with multiple lung nodules, including a tumor that was
dually positive for Me4FDG and FDG (t1) as well as two smaller nodules (t2 and t3). Tumors t2 
and t3 were positive for Me4FDG but negative for FDG and were included in the red box in figure 
2A. Using 3D rendering of the regions of interest to locate the exact position of the tumor nodules 
in the lungs (fig. S2A), we correlated the PET signal with tumor histology (fig. S2B) and IHC (fig. 
S2C). The larger t1 tumor, which was positive for both FDG and Me4FDG uptake, expressed both 
SGLT2 and GLUT1 (fig. S2C, top panels). Histological analysis shown for the smaller Me4FDG 
positive tumor t2 confirmed high SGLT2 and low GLUT1 expression (fig. S2C, bottom panels). 
We evaluated the minimum detection limit of Me4FDG to detect early-stage lung nodules 
by calculating the contrast-to-noise ratio (CNR) as described in (31). The lung background was 
evaluated by designing regions of interest corresponding to the normal lungs (fig. S2D). The 
formulas used for calculating the CNR are described in the Materials and Methods section. We 
used a stringent cut-off, setting the minimum detection level at lesions with a CNR ≥ 4. This 
analysis showed that CNR for Me4FDG is linearly related to lesion size, as expected (fig. S2E). 
Tumors t2 and t3 in fig. 2B had CNRs of 4.47 and 7.83, respectively. The smallest lesion with a 
CNR ≥ 4 for Me4FDG was t2 in fig. 2B, which measured 0.52 mm
3
in volume (1.0 mm diameter). 
IHC staining of this lesion showed SGLT2 positivity in 71% of the cells. Overall, quantification 
of the IHC signal showed that SGLT2 expression correlated with Me4FDG, as expected (fig. 2C).
Likewise, GLUT1 expression is correlated with FDG uptake (22, 32-34). 
The positive correlation between Me4FDG and FDG was not expected, considering the 
reciprocal pattern of SGLT2 and GLUT1 expression observed in the human specimens (fig. 1). 
However, upon closer inspection of nodules expressing both SGLT2 and GLUT1, we observed 
that the majority of advanced carcinomas expressed both transporters, but the two proteins usually 
did not co-localize in the same cells.  Rather, they were observed in different regions of the tumor 
nodules, highlighting the intra-tumor heterogeneity of glucose uptake (fig. 2D-G). Specifically, 
we noticed that SGLT2 was expressed in well-differentiated areas of the tumor, whereas GLUT1 
was more abundant in poorly differentiated regions, confirming the pattern already observed in 
human LADC. 
We therefore measured the IHC signal in sub-areas of the tumor nodules that could be 
clearly identified in the H & E staining as purely low-grade or high-grade (fig. S2F). Similarly to 
human LADC, the lung tumors in KPluc mice show a very heterogeneous morphology, with well-
and moderately differentiated areas (fig. S2G) coexisting with poorly differentiated cell clusters 
(fig. S2H). In many cases, poorly differentiated cells are interspersed within well- and moderately 
differentiated cells, in a mosaic pattern (fig. S2I). We therefore quantified SGLT2 and GLUT1 
expression only in the regions of interest (ROIs) corresponding to clearly discernible areas of the 
tumors that were purely low-grade (well- or moderately differentiated) or high-grade (poorly 
differentiated) (fig. S2F). This analysis showed that SGLT2 and GLUT1 expression was 
negatively correlated. We color-coded the ROIs as red corresponding to high-grade tumor regions 
and green corresponding to low-grade tumor regions in fig. 2D. Notably, the high-grade ROIs 
clustered with a GLUT1 positive signal, whereas low-grade ROIs clustered with a SGLT2 positive 
signal (fig. 2D). 
We next quantified SGLT2 and GLUT1 staining in lung tumors from KPluc mice. IHC staining in 
Fig. 2E shows adjacent sections of a representative sample stained with antibodies against SGLT2 
(upper panel) and GLUT1 (lower panel), and fig. 2F presents the corresponding hematoxylin-eosin 
(H & E) staining. The area to the left of the blue line is well differentiated and has high SGLT2 
and low GLUT1 expression; the region to the right of the blue line is poorly differentiated and 
shows low SGLT2 and high GLUT1 signal. Quantification of signal intensity in all lung tumors
from n = 7 mice showed a significantly higher SGLT2 staining in low-grade areas of the tumors 
(p < 0.001) and higher GLUT1 signal in high-grade areas (p < 0.001) (fig. 2G and table S2). This
heterogeneity of glucose transport mirrors the heterogeneity observed in human tumors. Human 
LADCs often present with a mix of well to poorly differentiated tumor cells. We found several 
instances in which different areas of the same tumor stained with either SGLT2 or GLUT1 in a 
mutually exclusive pattern (fig. 2H-I). SGLT2 staining was confined to well and moderately 
differentiated areas, whereas GLUT1 staining was localized in poorly differentiated regions of the 
same tumor. Taken together, these data show that SGLT2 and GLUT1 represent two independent 
mechanisms of glucose uptake in cancer cells, with SGLT2 prevalent in low-grade LADC and 
GLUT1 prevalent in high-grade LADC. 
Premalignant and early LADCs predominantly use SGLT2 to transport glucose into tumors
Our data suggested that Me4FDG may detect early LADC lesions that are FDG-negative, yet 
metabolically active. They also supported the premise that SGLT2 expression is an early event in 
LADC oncogenic transformation. 
In order to identify the stage of lung carcinogenesis in which SGLT2 is first upregulated, 
we performed serial IHC in KPluc GEMMs 2, 5, and 8 weeks after tumor induction (fig. 3A-D). 
Premalignant AAH lesions developed in these mice as early as 2 weeks after tumor induction. By 
week 5, small adenomas were observed, and by week 8 the mice had advanced adenocarcinomas 
(fig. 3A). Immunohistochemistry showed that SGLT2 expression was highest in premalignant 
lepidic lesions at week 2 and progressively diminished in early adenomas and in advanced LADC 
(fig. 3B, upper panels). Conversely, GLUT1 expression was not detectable in early lesions at week 
2, but became progressively stronger as the tumors progressed to adenomas and advanced LADC 
(fig. 3B, lower panels), suggesting an evolution in the pattern of expression of glucose transporters, 
with SGLT2 exclusively expressed in early stages and both SGLT2 and GLUT1 present in a 
mosaic pattern in late stages of lung carcinogenesis. Quantification of the signal confirmed a 
significant decrease in SGLT2 (p < 0.001) and increase in GLUT1 (p = 0.048) as the tumors 
became more advanced (fig. 3C-D and table S3). 
To better characterize the evolution of SGLT2 and GLUT1 activity during lung 
tumorigenesis, we performed a time course of repeat Me4FDG and FDG PET imaging on KPluc
mice. The first PET scan was performed when lung nodules reached an average size of 7 mm
3
, 
followed by two bi-weekly scans with a total of three time points. Analysis of tracer uptake at 
different time points showed that Me4FDG was taken up in early lesions, which were mostly 
negative for FDG (fig. 3E, time point 1). As the tumors progressed and became more advanced,
they increased their uptake of FDG, while Me4FDG uptake remained constant, as shown in 
representative PET/CT imaging (fig. 3E, time points 2 and 3 and fig. S3). Quantification of tracer 
uptake in all the lung nodules included in the study (n = 16 tumors in 7 mice) confirmed that early 
tumors had high Me4FDG and low FDG uptake, whereas later stage tumors were more 
heterogeneous, with a slightly reduced Me4FDG uptake and significant up-regulation of FDG 
uptake (p < 0.001) (fig. 3F-G). These results are consistent with the expression of both transporters 
in advanced tumors shown in fig. 2E-G and with the positive correlation between Me4FDG and 
FDG uptake observed in advanced tumors represented in fig. 2A.
Taken together, these data show that early-stage lung adenocarcinomas and pre-malignant 
lesions express SGLT2 and use only sodium-dependent transport for glucose uptake, whereas more 
advanced lesions upregulate GLUT1 expression. These results suggest a complex and spatially 
heterogeneous pattern of glucose uptake that engages both SGLT- and GLUT-dependent glucose 
transport during LADC progression (fig. 3H-I).
Gliflozins suppress growth of early stage LADC and extend survival in KPluc GEMMs 
Because we observed only SGLT-dependent glucose uptake in early-stage lung nodules, we 
hypothesized that SGLT2 is required for tumor growth in the early stages of lung carcinogenesis. 
Therefore, we reasoned that pharmacological inhibition of SGLT2 would slow tumor development 
in KPluc GEMMs and extend overall survival. Gliflozins are FDA-approved drugs for the treatment 
of diabetes (35, 36) and have been tested against pancreatic cancer in xenografts (25). Gliflozins 
function by inhibiting glucose reabsorption in the kidneys, resulting in significant (p < 0.01) 
excretion of Me4FDG in the urine (fig. 4A-B). We first confirmed that gliflozins were selective 
inhibitors of SGLT2 activity by performing Me4FDG PET imaging on KPluc mice, with or without 
co-administration of a single intravenous dose of the SGLT2 inhibitor dapagliflozin (25, 37). As 
anticipated (25, 38), dapagliflozin reduced Me4FDG uptake in the tumors, as well as in the heart, 
liver, and skeletal muscle (fig. 4A-B). 
We then performed preclinical studies on KPluc mice to test the SGLT2 inhibitor 
canagliflozin, which was recently approved by the FDA for diabetes and reported to be a more 
effective SGLT2 inhibitor than dapagliflozin (39). We started treatment with canagliflozin (30 
mg/kg/d by oral gavage) (25) two weeks after tumor induction, when only premalignant lesions 
were present (fig. 3A-B). We performed two experiments: in the first trial we treated mice for 6 
weeks, followed by sacrifice and histological analysis of lungs and tumors (n = 12 mice per group); 
in the second trial we treated mice for up to three months for survival analysis (n = 15 mice per 
group) (fig. 4C). Tumor burden, estimated by bioluminescence imaging (BLI), was significantly 
lower (p < 0.001) in the treatment than the placebo group (fig. 4D-E). Quantification of the BLI 
signal for both treatment groups up to week 8 showed that canagliflozin significantly delayed the
onset of tumors compared to the placebo group (p < 0.001). Additionally, plotting the BLI for 
individual animals up to the end of the trial at week 14 showed that the BLI signal remained lower 
in the treatment group as compared to the placebo group (fig. S4A). The BLI values of individual 
mice in the survival and the week 8 cohort are presented in table S4 and S5, respectively. 
Histological analysis of the lungs and measurement of tumor area confirmed that canagliflozin 
treated mice had a significantly lower tumor burden than in the placebo group (p < 0.05), both at 
8 weeks and in the survival cohort (fig. 4F-G). A Ki67 stain of the mouse tumors showed a 
significantly lower (p = 0.001) proliferation rate in the canagliflozin treatment group compared 
with that in the placebo group, but only in premalignant lesions (fig. 4H-I) and not in solid LADC 
(fig. S4B-C), suggesting that SGLT2 inhibition may target premalignant lesions with higher 
efficacy than advanced carcinomas. This is consistent with the observation that SGLT2 is 
expressed predominantly in early lesions. 
Overall, canagliflozin treatment significantly prolonged mouse survival (p = 0.0003) compared 
with the placebo group (fig. 4J). However, tumors eventually escaped SGLT2 inhibition and 
formed large tumor masses even within the canagliflozin group (fig. 4F). We analyzed SGLT2 
expression in the lungs of mice from both treatment groups and showed that SGLT2 expression 
was low in the placebo group, with only 17% of tumor cells staining positive for SGLT2,
consistently with the advanced nature of these tumors. Tumors in the canagliflozin group had 
significantly higher SGLT2 expression (p < 0.0001): 30% of the tumor cells had positive SGLT2 
staining (fig. S4D-E). This suggests that over-expression of the transporter may be a compensatory 
mechanism induced by SGLT2 inhibition. Taken together, these data suggest that SGLT2-
mediated glucose transport is an early requirement for lung carcinogenesis and may sustain the 
increased proliferation rate associated with progression from premalignancy to invasive cancer 
and tumor growth.
Me4FDG PET-guided inhibition of SGLT2 activity in LADC reduced tumor growth in patient-
derived xenografts
We next performed a therapeutic trial with canagliflozin (30 mg/kg/d by oral gavage for one 
month) (25) in the same four PDXs presented in fig. 1E to test the relevance of targeted SGLT2 
inhibition in human cancers (fig. 5). Mice were imaged by Me4FDG and FDG PET/CT before 
treatment and 2 weeks after starting treatment. Weekly CT scans were acquired to monitor tumor 
burden. The mice were sacrificed and the tumors analyzed after 1 month of treatment (fig. 5A). 
Overall, we observed a significant (p = 0.003) reduction in tumor volumes in the treatment group 
compared with the placebo group. Treated mice had final tumor volumes approximately 47% lower 
than the control mice (geometric mean ratio 0.53, 95% CI: 0.36-0.80, p = 0.003), after adjusting 
for trial and mouse random effects (fig. 5B). 
Despite the variability in SGLT2 staining between moderately and poorly differentiated 
PDXs shown in fig. 3E, all four PDXs displayed a detectable uptake of Me4FDG and a similar 
response to SGLT2 inhibition (fig. 5C-D). This was expected, considering that these PDXs were 
not purely SGLT2-positive or SGLT2-negative, but in each PDX well and moderately 
differentiated, SGLT2-positive areas coexisted with poorly differentiated, SGLT2-negative areas 
of the same tumor (fig. S5). 
Overall, Me4FDG uptake increased from day 0 to day 14 in the placebo group, whereas 
canagliflozin significantly reduced Me4FDG uptake (p < 0.001), as expected (fig. 5C-D). Notably, 
Me4FDG uptake before treatment in the placebo group significantly correlated with tumor volume 
fold change from the beginning to the end of the trial (p < 0.001), confirming an important role of 
SGLT2-dependent glucose uptake in the regulation of tumor growth (fig. 5E). In the canagliflozin 
group, Me4FDG scans before treatment showed no significant correlation with tumor volume fold 
change (fig. 5F). Moreover, the percent reduction of Me4FDG uptake observed after canagliflozin 
treatment negatively correlated with the fold increase in tumor volume (p = 0.027), confirming 
that a reduction in Me4FDG uptake after treatment can be used as a marker of response to SGLT2 
inhibition (fig. 5G). In contrast, FDG signal did not significantly change from day 0 to day 14 in 
either the placebo or the canagliflozin group (fig. 5H-I). In addition, pre-treatment uptake or 
changes in FDG uptake between pre- and post-treatment did not correlate with the fold change in 
tumor volume (fig. 5J-L). These data support the premise that SGLT2 inhibition may be effective 
in retarding the growth of early lesions that rely on SGLT2 for glucose uptake and that Me4FDG 
may be used to evaluate the response to therapeutic inhibition of SGLT2.
Discussion
In this study we present evidence that sodium-dependent glucose transporter 2 (SGLT2) is a 
glucose transport mechanism specifically active in pulmonary pre-malignant lesions and in early 
LADC. We show expression of SGLT2 protein by IHC with specific antibodies in human LADC 
specimens, in genetically engineered murine models, and in patient-derived xenografts of LADC. 
We also report SGLT2-dependent uptake of the PET tracer Me4FDG in vivo both in genetically 
engineered and in patient-derived murine models. Finally, we confirm that SGLT2 inhibitors delay 
LADC development and growth in murine models, suggesting SGLT2 inhibition as a potential
therapeutic strategy for pre-malignant and early stage LADC. Our data highlight the importance 
of sodium-dependent glucose transport in early stages of LADC development, both in human 
tumors and in murine models.
Our data suggest that there is a progression of glucose transporter expression during LADC 
carcinogenesis: early-stage lesions express only SGLT2, whereas more advanced lesions display 
a spatially complex and heterogeneous pattern of SGLT2 and GLUT1 expression. Consistently, 
early-stage tumors accumulate only Me4FG and not FDG, whereas advanced tumors take up both 
tracers. SGLT2 is most prominent in well-differentiated tumor cells, whereas GLUT1 becomes 
prevalent in poorly differentiated tumor cells. The mechanisms that drive this evolution in glucose 
transport in cancer are unknown and will need to be the subject of future investigations.  However, 
we hypothesize that hypoxia is a major driver of the transition from SGLT2- to GLUT1-dependent 
glucose uptake in LADC. Hypoxia inducible factor 1α (HIF1α) up-regulates GLUT1 expression 
(40-42). We therefore speculate that pre-malignant and early-stage lesions, which are well 
oxygenated and perfused, preferentially express SGLT2. In contrast, it may be that in advanced 
hypoxic lesions, GLUT1-mediated glucose transport dominates the tumor landscape.
The discovery of SGLT2 expression in pulmonary premalignancy and early LADC has 
important diagnostic and therapeutic applications. The National Lung Screening Trial (NLST) has 
shown that low-dose helical computed tomography (CT) in older, high-risk smokers can reduce 
lung cancer-related mortality by 20% compared with chest X-ray (43). However, CT imaging lacks 
specificity in distinguishing benign from malignant solitary pulmonary nodules (44). Moreover, 
high-resolution CT has increased the detection rates of indeterminate lung lesions (45), including
both benign lesions and premalignant or early adenocarcinomas (46-48), which require additional 
imaging or invasive procedures for diagnosis. FDG PET has proven to be ineffective in identifying 
premalignancy or early LADC (17, 23), particularly in the setting of subsolid nodules (15-17) such 
as AAH, AIS, or MIA lesions (3, 14). Notably, 73% of patients in the NLST with benign lesions 
required invasive diagnostic procedures (49). In addition to the costs and potential complications 
associated with these procedures, a quality of life (QOL) study on the impact of low-dose CT 
(LDCT) screening found that 46% of patients reported psychological distress while awaiting 
imaging results (50). This is particularly notable when considering that 16% of lesions identified 
on baseline screening LDCT in the NLST were ground-glass opacities that demonstrated relatively 
constant annual rates of lung cancer diagnosis over the course of six years of follow-up. Subsolid 
lung nodules commonly represent the early spectrum of LADC and may persist for years before 
malignant progression. Improved diagnostic tools could potentially reduce cost, invasive 
procedures, and radiation exposure, as well as improve QOL for patients with indeterminate lung 
nodules requiring surveillance. In addition to GGNs identified incidentally or by screening, it is 
common to detect multiple GGNs in patients who undergo surgery for an invasive LADC; 
Me4FDG PET could aid the follow-up of these lesions and help predict the risk of progression to 
invasive cancer.
We present evidence that in premalignant and early lepidic lesions, cellular glucose uptake 
occurs via SGLT2 rather than GLUT1 to satisfy metabolic demands. Therefore, it is anticipated 
that measurement of SGLT-mediated glucose utilization with the tracer Me4FDG will be valuable 
in classifying subsolid nodules as benign disease or early lesions within the spectrum of
adenocarcinoma.  This has the potential to answer an unmet need in the field of lung cancer that 
CT and FDG PET alone cannot address. Our next goal is to extend this work to clinical trials to 
evaluate Me4FDG for the diagnostic characterization of indeterminate lung nodules and GGNs 
and for predicting the clinical behavior of these lesions.
We have also shown that SGLT2 inhibitors hinder tumor progression by limiting glucose 
supply in cancer cells and that Me4FDG can be used to evaluate the response of LADCs to SGLT2 
inhibition by PET imaging before and after receiving treatment. Specific SGLT2 inhibitors 
(gliflozins), which are FDA-approved for the treatment of diabetes, function by lowering the renal 
threshold for glucose reabsorption and therefore induce glycosuria and reduce blood glucose in 
diabetic patients (35, 36). We have previously shown that gliflozins have antitumor activity against 
pancreatic tumors in a xenograft model (25). Here, we found that gliflozins specifically target lung 
premalignancy, effectively reduce tumor burden, and prolong survival if administered at an early 
stage. Of note, our studies in PDX models treated with canagliflozin showed that Me4FDG uptake 
before treatment correlated with tumor volume fold decrease after treatment.  This suggests that 
Me4FDG PET imaging could help identify individuals with premalignancy or early LADC with 
active SGLT2 transporters. In this context, gliflozin therapy could be applied as a cancer 
interception strategy to prevent or delay malignant progression of subsolid lesions detected by
Me4FDG PET and CT (8, 9).  This strategy would serve patients with other tobacco-associated 
cardiopulmonary diseases who are poor candidates for surgical resection.  The ability to reliably 
detect premalignant and early stage lung adenocarcinomas with the use of Me4FDG PET could
enable more timely interventions, interrupting the progression to invasive, more advanced disease 
and thus improving long-term outcomes.
Finally, we observed that Me4FDG PET, by detecting SGLT-dependent glucose transport 
in vivo, can be used to assess response to treatment with SGLT2 inhibitors. In particular, 
measurement of Me4FDG uptake in PDXs before and after beginning gliflozin treatment allowed 
us to establish an inverse correlation between the reduction in Me4FDG uptake as a consequence 
of the treatment and the rate of tumor volume increase. In patients with FDG-avid tumors, 
monitoring metabolic responses to drug therapy can be relevant for prognostic assessment and 
clinical decision-making regarding treatment (51-53). Me4FDG PET in mice showed similar if not 
better minimal detection limits in early stage lesions compared to FDG PET and would be expected 
to perform in an equivalent manner in humans (54). Therefore, we anticipate that PET 
measurement of SGLT activity in lung premalignancy and adenocarcinomas before and after the 
beginning of treatment will provide an invaluable precision medicine tool to evaluate the response 
of pre-malignant lesions to SGLT2 inhibitors. 
This study has some limitations. First, we were not able to demonstrate a significant 
correlation between SGLT2 expression and tumor stage. This is probably due to the low number 
of samples, especially considering that most surgical samples in the UCLA tumor bank were from 
early-stage tumors, with relatively low number of advanced LADCs. However, we were able to 
find a specific profile of SGLT2 expression in lepidic and well-differentiated lesions. Second, we 
demonstrated Me4FDG uptake in GEMMs and in PDXs but not in LADC patients; this will be the 
focus of our next studies. Third, we cannot exclude that the effect of SGLT2 inhibitors on tumor 
volume and mouse survival is due to a systemic effect of lowering blood glucose rather than to the 
inhibition of glucose uptake in the tumor. The conditional knockout of SGLT2 in the KP model 
will discriminate between these two possibilities, and is the focus of our future investigations. 
Materials and Methods
Study Design
Purpose of this study was to evaluate SGLT2 as a diagnostic and therapeutic target for early-stage 
lung cancer. We validated this by immunohistochemistry in human LADC specimens and by PET 
imaging and therapeutic trials in mouse models. For the immunohistochemistry in human 
specimens, purpose of the analysis was to assess the correlation between SGLT2 expression and 
tumor grade and stage. Samples of lung adenocarcinoma were retrospectively selected from the 
UCLA lung tumor bank according to the pathologic grade and stage. The quantification of the 
signal was performed blindly by a board-certified pathologist (W. D. W.) using the Aperio 
ImageScope software. For the imaging and therapeutic trials in mouse models, we used a Kras
G12D
-
driven, p53-null GEMM and patient-derived xenografts of human LADC in Non-obese diabetic 
(NOD), Severe combined immunodeficiency (SCID), interleukin 2 receptor Gamma knockout
(NSG) mice. Mice were stratified to make the treatment groups comparable for mouse age (22.3 
± 0.54 weeks), sex (63% female, 47% male), body weight (33.5 ± 0.66 grams), and tumor burden 
(estimated by bioluminescence signal in the GEMMs and by volumetric determinations from CT 
scans in PDXs). To determine the group size, we used a generalized estimating equation (GEE) 
model (56) to compare tumor size curves over time and assuming a two-sided 0.05 level of 
significance. With 12 mice per group we calculated 86% power; therefore, for our therapeutic trials 
we used groups of at least 12 mice. The tumor burden in the experimental groups was evaluated 
by objective measurements: 1) for the GEMMs, weekly bioluminescence measurements 
throughout the study; 2) for the PDXs, measurement of tumor volumes from CT scans, performed 
by designing blindly regions of interest encompassing the whole tumor volume; 3) measurement 
of tumor area by Definiens software in histologic lung sections stained with hematoxylin and eosin. 
Mouse models
All experiments performed in mice were approved by the University of California Los Angeles 
Institutional Animal Care and Use Committee and were carried out according to the guidelines of 
the Department of Laboratory Animal Medicine at UCLA. All mice were housed in pathogen-free 
facilities at UCLA.
Genetically engineered mouse model. For our imaging and therapeutic trials in genetically 
engineered mouse models, we used Lox-Stop-Lox Kras
G12D
, p53
lox/lox
, Rosa26-Lox-Stop-Lox-Luc 
mice previously established in our lab, inbred on an FVB background. The mice were bred in our 
colony at UCLA. Lung tumors were induced by intranasal administration of Adeno-Cre (purchased 
from University of Iowa adenoviral core) as previously described (30). After tumor induction, the 
tumor burden was estimated by weekly bioluminescence performed on an IVIS Spectrum in vivo 
imaging system (Perkin Elmer) 10 minutes after intraperitoneal injection of luciferin (150 mg/kg). 
Patient-derived xenografts (PDXs). The tumor samples were obtained from surgically 
resected specimens after informed consent under the UCLA Lung SPORE (PDX #004 and #011) 
or the Long Beach Memorial Hospital IRB protocol (PDX #013). One of the PDXs (#186) was 
purchased from Jackson Laboratories. PDXs were established and passaged in NSG mice. NSG 
mice were procured from the UCLA Radiation Oncology breeding colony. For each mouse, two 
small pieces of tumor tissue (~2 mm
3
) were implanted subcutaneously in the flank regions.
MicroPET imaging
For the PET imaging experiment in the genetically engineered mouse model presented in fig. 2, 
the mice were scanned 12 weeks after the Adeno-Cre inhalation (1/200 dilution). For the time-
course imaging in fig. 3E-G, the mice received a much lower dilution of AdenoCre (1/10,000),
and the mice were imaged when the average lung nodule maximum diameters were around 7 mm. 
For the microPET in patient-derived xenografts, a subset of the mice (PDXs #004, #013, and #186) 
received both Me4FDG and FDG PET scans the day before and 2 weeks after the beginning of 
treatment, to evaluate the response of glucose transporter activity to the treatment.
The animals were anesthetized with 1.5% (vol/vol) isoflurane in oxygen, were given a dose 
of 100 μCi Me4FDG or FDG via tail vein injection, and were maintained under anesthesia for 1
hour of unconscious uptake. The mice were then immobilized on the imaging bed and received a 
10 min static PET scan followed by CT scan. Each mouse received two different PET scans with 
the two tracers (Me4FDG and FDG), on consecutive days to allow for tracer decay. The equipment 
used was Focus 220 microPET scanner (Concorde Microsystems) and Inveon microPET scanner 
(Siemens) for the microPET scans, and CrumpCAT (UCLA Crump Institute) for the microCT. 
The PET data were analyzed with Amide software version 1.0.4 (amide.sourceforge.net/) 
(55). Regions of interest for the measurement of tumor uptake were drawn corresponding with 
single lung nodules as identified by CT images. For the GEMMs, which typically present with 
small intrathoracic nodules with regular shape, ellipsoid ROIs were considered to be an acceptable 
approximation of tumor volume. For advanced lung nodules which did not have perfectly ellipsoid 
shape and smooth borders, the ROIs were placed in the center of the tumor nodule, to include as 
much tumor volume as possible inside the ROI. To compare FDG and Me4FDG uptake, the same 
ROIs were used in the same mice scanned with the two different tracers, such that comparable 
tumor volumes were measured with the two tracers. For the PDXs, which typically show larger 
and irregularly shaped tumors, isocontour regions of interest were designed based on the CT scans 
to encompass the whole tumor volumes. The percentage of injected dose for each ROI was 
calculated by dividing the measured activity in the ROI by the total injected dose, as measured 
from the PET image by designing an ROI encompassing the whole mouse. The analysis of signal 
to noise ratio in the mouse nodules was performed as described in (31). Briefly, we evaluated the 
background signal for each mouse by designing a region of interest corresponding to the normal 
lung (fig. S2D). We then calculated the contrast to noise ratio (CNR) for each nodule by using the 
following formula (31):
    ≈    ×     ×	         (1)
where Cl is the lesion to background contrast, nl is the number of pixels in the region of interest, 
and SNRpixel is the signal to noise ratio for a single pixel in the background:
   =	
   	  
  
and          =	
  
  
(2)
The smallest lesion activity that can generate a CNR greater than 3–5 is called the minimum 
detectable activity. For the purpose of this analysis, we considered a CNR ≥ 4 as specific signal.
Therapeutic studies in mice
Genetically engineered mouse model. Tumors were induced in KPluc mice by inhalation of Adeno-
Cre (1/10 dilution). Two independent trials were performed, starting two weeks after tumor 
induction. In the first trial (n = 12 mice per group), mice were treated for 6 weeks and then 
sacrificed for lung collection and fixation in formalin. In the second trial (n = 15 per group), mice 
were treated until death for survival analysis. The two therapeutic groups were: 1) placebo, 
receiving daily oral gavage with vehicle: 0.5% hydroxypropyl-methyl cellulose; 2) canagliflozin, 
receiving a daily dose of canagliflozin (30 mg/kg via oral gavage), as previously described (25). 
In the survival cohort, two mice (#3416 and #3418) were censored on day 45 and 57, respectively, 
for esophageal rupture due to complication of the oral gavage. 
Patient-derived xenografts. The mice were randomized in two therapeutic groups (same as 
for the trials in GEMMs): placebo and canagliflozin (30 mg/kg/d). The number of mice per group 
was 4 for PDX #011, 8 for PDX #013, 3 for PDX #004, and 5 for PDX #186; each mouse was 
inoculated with two tumors (one tumor on each flank); some of the tumors of PDX #011 developed 
soft tissue metastases in the axillary regions, and these were counted as separate tumors. Overall, 
38 tumors were included in the placebo and 39 tumors in the canagliflozin group. The mice were 
treated for one month, then sacrificed, and the tumors collected for histology and IHC. The mice 
of PDX #011 were treated only for 2 weeks, because extremely rapid tumor growth in the placebo 
group required premature sacrifice of the animals. The tumor volumes at 2 weeks were counted as 
final tumor volumes.
Immunohistochemistry
For the GEMMs, the mouse lungs were collected and inflated with 10% formalin in phosphate-
buffered saline, then incubated in formalin for 24 hours. For the PDXs, subcutaneous tumors were 
collected and incubated in formalin for 24 hours. All tissues were paraffin-embedded and sliced 
into 4-μm sections in the Translational Pathology Core Laboratory (TPCL) at UCLA. For human 
lung cancer samples, tissue blocks were obtained anonymously from the UCLA Lung SPORE 
tissue bank and from Long Beach Memorial Hospital.
For IHC staining, the slides were de-paraffinized by overnight incubation at 65ºC followed
by rehydration by serial passages in xylenes (3 washes of 5 minutes in 100% xylenes) and 
decreasing concentrations of ethanol (2 washes in 100% ethanol, 2 in 95%, 1 in 80%, 1 in 70%, 1 
wash in water). Antigen retrieval was performed for 20 min in 10 mM Tris-HCl, 1 mM EDTA (pH 
8.0) for SGLT2 and GLUT1 antibodies, and in 10 mM citrate (pH 6.0) for Ki67. Blocking was 
performed with 5% goat serum for 1 hour at room temperature, followed by incubation with 
primary antibodies overnight at 4ºC. Incubation with biotin-labeled secondary antibody was 
performed at room temperature for 1 hour, followed by incubation with avidin-biotin peroxidase 
complex (ABC, Vector Labs) and ImmPACT DAB (Vector Labs) for 1 minute. Counterstain was 
performed with Harris’ hematoxylin diluted 1:5 in water. For SGLT2, two different antibodies 
were used: Abcam ab85626 (1:1000) for mouse tissues, and Novus Biologicals NBP1-92384 
(1:250) for human and mouse tissues. The antigenic peptide for the Novus antibody is 
FHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLL; for the Abcam 
antibody the sequence is proprietary, but included in residues 250-350 of human SGLT2. For 
GLUT1, the Alpha Diagnostics GT11A antibody (1:200) was used. For Ki67, the Thermo 
Scientific SP6 antibody (1:200) was used.
After the staining, digital images of the slides were obtained with the Aperio ScanScope 
slide scanner (Leica Biosystems). For the mouse tissues, the IHC signal was quantified with the 
Definiens Tissue Studio software. For the human tissues, the quantification was performed blindly 
by a board-certified pathologist (W. D. W.) using the Aperio ImageScope software. 
Statistical analyses
The association between SGLT2 expression and Me4FDG uptake in mouse tissue was assessed 
using a generalized estimating equation (GEE) model (56) to accurately account for the same 
mouse being measured multiple times (multiple tumors per mouse or same mouse over time). We 
ran a similar model for testing the association between SGLT2 and GLUT1 expression. The 
associations were also quantified using Pearson’s correlation coefficient. The association between 
time (weeks 2, 5, 8) and SGLT2 (or GLUT1) was formally assessed using the Jonchkeere-Terpstra 
test for ordered alternatives.
For the human samples, SGLT2 expression was computed using a weighted average, where 
each staining score assigned by the Aperio software (3+: very strong; 2+: strong; 2+: light; 1+: 
very light; 0: no signal) was multiplied by the corresponding percentage of cells in each sample. 
We then assessed the directional association between morphology categories (lepidic – moderately 
differentiated – poorly differentiated) and SGLT2 or GLUT1 score using the Jonchkeere-Terpstra 
test. Statistical analyses were performed using SPSS V24.
For the therapeutic trials in the GEMMs, tumor growth curves (slopes) were compared between 
canagliflozin and control groups using GEE models (56) with terms for time, group, and the time 
by group interaction. These models also included a random effect for mouse to account for the 
repeated observations of tumor size over time. We used log transformations to normalize the tumor 
size outcomes. For the therapeutic trials in PDXs, a linear mixed effects model for log tumor 
volume was used, with terms for fixed effects (treatment group) and random effects (PDX trial; 
mice within trial clustered random effect: 38-39 distinct tumors in 20 distinct mice). The data 
analysis was performed using proc mixed from the software SAS V9.4. All other group 
comparisons were performed using the two-sample t-test unless otherwise noted. P-values < 0.05 
were considered statistically significant throughout the manuscript.
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Figures
Fig. 1. SGLT2 is expressed in low-grade and GLUT1 in high-grade human lung 
adenocarcinoma
Immunohistochemistry was performed in human LADC samples with antibodies specific for 
SGLT2 and GLUT1. A) Invasive adenocarcinomas, different disease grades, as indicated. B) 
Quantification of SGLT2 (upper panel) and GLUT1 (lower panel) staining in different disease 
grades of LADC, measured by Jonchkeere-Terpstra test. ***p < 0.001. Scale bars: 50 μm. C) 
Normal alveoli. D) Pre-malignant lesions: atypical adenomatous hyperplasia, adenocarcinoma in 
situ, and minimally invasive adenocarcinoma. Scale bars: 50 μm (insert: 25 μm). E) Expression of 
SGLT2 and GLUT1 in different PDX models of LADC: well-moderately differentiated (PDX 
#004), moderately differentiated (PDXs #186 and #011), and poorly differentiated (PDX # 013). 
Scale bars: 50 μm.
Fig. 2. Glucose transporter expression and activity in lung adenocarcinoma is heterogeneous.
A) KPluc mice were imaged with Me4FDG and FDG; the scatter plot reports the uptake of ROIs 
corresponding to single LADC nodules, expressed as percentage of injected dose per gram of tissue 
(%ID/g). The red box highlights tumors with high Me4FDG and low FDG uptake. The correlation 
was calculated using Pearson’s coefficient (r). B) Representative transverse sections of the 
PET/CT images show three distinct tumor nodules, t1, t2, and t3. Uptake of Me4FDG is detectable 
in small nodules (t2 and t3), which are FDG-negative. C) Pearson correlation between Me4FDG 
uptake in lung adenocarcinomas and SGLT2 protein expression as measured by 
immunohistochemistry. The p-value was calculated from generalized estimating equation (GEE) 
models (56). D) Pearson correlation between SGLT2 and GLUT1 protein expression in regions of 
interest corresponding to small areas of the tumor which were clearly identified in the H&E 
staining as purely low-grade or high-grade, as outlined in fig. S2F. The ROIs encompassing tumor 
areas with high-grade histology are reported as red circles, and the ROIs corresponding to low-
grade tumor areas are represented by green triangles. E) Representative images of SGLT2 and 
GLUT1 expression in low- and high-grade tumor areas. Scale bars: 100 μm (inserts: 10 μm). F) 
Hematoxylin and eosin stain in an adjacent section shows the different morphology of the low-
and high-grade tumor areas. Scale bars: 100 μm (inserts: 10 μm). G) SGLT2 and GLUT1 protein 
expression was compared between low- and high-grade tumors using GEE models. ***p < 0.001. 
H) Representative images of a human adenocarcinoma, adjacent slices of which were stained for 
SGLT2 (upper panel) or GLUT1 (lower panel). Scale bar: 1 mm. I) Higher magnification of a 
well-differentiated (blue squares) and a poorly differentiated (red squares) area of the samples 
presented in H. Scale bar: 100 μm.
Fig. 3. SGLT2 is expressed in early LADC and GLUT1 in advanced LADC in KPluc GEMMs
A) Schematic representation and whole-lung hematoxylin and eosin stain of LADC progression in 
KPluc mice at different time points after tumor induction, as indicated. Scale bar: 1 mm. B) Time 
course of SGLT2 and GLUT1 expression in KPluc mouse lung lesions at different time points after 
tumor induction. Scale bar: 50 μm. C-D) Quantification of the SGLT2 (C) and GLUT1 (D) 
immunohistochemistry signal at different time points after tumor induction in KPluc mice, 
measured by Jonchkeere-Terpstra test. *p ≤ 0.05; ***p ≤ 0.01. E) Time course of Me4FDG and 
FDG imaging in KPluc mice. The first time point was taken when tumor nodules reached an average 
diameter of 7 mm, and the subsequent time points were performed at 2-week intervals. F-G)
Quantification of Me4FDG (F) and FDG (G) signal in all 7 mice included in the cohort (with a 
total of 16 tumors). H-I) Schematic representation of glucose transporter expression in different 
stages of LADC: premalignant lesions and early-stage LADC express only SGLT2 (H), whereas 
advanced tumors show spatial heterogeneity of glucose transport expression, with SGLT2 in well-
differentiated and GLUT1 in poorly differentiated areas of the same tumor (I).
Fig. 4. SGLT2 inhibition delays development of lung adenocarcinomas in KPluc GEMMs.
A-B) The effect of single-dose SGLT2 inhibitor dapagliflozin on SGLT activity was evaluated by 
Me4FDG PET. A) Representative 3D rendering of the PET/CT in the same KPluc mouse imaged 
on different days with Me4FDG without or with co-injection of dapagliflozin. B) Comparison of 
Me4FDG uptake in n = 5 mice, expressed in percent of injected dose per gram of tissue (% ID/g)
in regions of interest corresponding to single lung nodules (upper panel) and to the bladder (lower 
panel). Uptake was compared between groups using the two-sample t-test. ****p < 0.0001; **p < 
0.01. C) Schematic representation of the therapeutic trials. GEMM: genetically engineered mouse 
model. AdenoCre: adenovirally encoded Cre recombinase. AAH: atypical adenomatous 
hyperplasia. ADC: adenocarcinoma. D-J) Therapeutic trial in KPluc mice treated with placebo or 
canagliflozin starting 2 weeks after tumor induction and carried on for either 6 weeks (Week 8 
cohort) or up to 3 months (Survival cohort). D) Representative images of bioluminescence in two 
mice belonging to the two treatment groups. E) Quantification of the bioluminescent signal in the 
two therapeutic groups over time. The p-value presented was from the interaction term between 
time/group from a generalized estimating equation (GEE) model (56). F) Representative 
hematoxylin and eosin stain of mouse lungs in the two treatment groups from both trials. Scale 
bar: 5 mm. G) Quantification of the tumor area in the Week 8 and Survival cohorts. Tumor size 
was compared between placebo and canagliflozin groups using the two-sample t-test. *p < 0.05. 
H-I) Ki67 staining in premalignant lesions: H) representative images; I) quantification of the signal 
in the two groups. The groups were compared using t-test. Scale bars: 50 µm. J) Overall survival 
curves for each group were constructed using the Kaplan-Meier method and formally compared 
using the log-rank test.
Fig. 5. SGLT2 inhibition of Me4FDG positive LADC slows down tumor growth in patient-
derived xenografts (PDXs).
A) The mice carrying PDXs were treated with 30 mg/kg canagliflozin for 1 month. They were 
imaged with Me4FDG and FDG PET/CT one day before and two weeks after the beginning of 
treatment; in addition, the mice received weekly CT scans to monitor tumor growth. B) Final tumor 
volumes on the last day of the trial, as measured by CT; the groups were compared using a linear 
mixed effects model for log (volume) with adjustment for trial and mouse random effects.
C-G) Results of the Me4FDG PET imaging in the mice included in the therapeutic trial. C) 
Representative PET/CT images in transversal section of two mice, one in the placebo and one in 
the canagliflozin group, injected with Me4FDG before (day 0) and after (week 2) the beginning of 
the treatment. The Me4FDG scans presented are from the same two mice. White arrows: tumor. 
Yellow arrowhead: bladder. D) Quantification of Me4FDG uptake in the tumors, expressed as 
percentage of injected dose per gram of tissue, in all the mice included in the trial, measured by t-
test. ***p < 0.001, **p < 0.01. E) Correlation between pre-treatment Me4FDG uptake in the 
tumors in the placebo group and the fold increase in volume from the beginning to the end of the 
therapeutic trial. Pearson’s correlation coefficient (r) and p-value are reported. F) Correlation 
between pre-treatment Me4FDG uptake in the tumors in the canagliflozin group and the fold 
increase in volume from the beginning to the end of the therapeutic trial. Pearson’s correlation 
coefficient (r) and p-value are reported. G) Correlation between the percent change in Me4FDG 
uptake from the beginning to week 2 of the therapeutic trial and the fold increase in volume from 
the beginning to the end of the therapeutic trial; Pearson’s correlation coefficient (r) and p-value 
are reported. H-L) Results of the FDG PET imaging in the mice included in the therapeutic trial.
The panels report the data relative to FDG uptake in the same mice presented in C-G. H) 
Representative PET/CT images in transversal section. White arrows: tumor. I) Quantification of 
FDG uptake in the tumors (n.s.: not significant). J) Correlation between pre-treatment FDG uptake 
in the tumors in the placebo group and the fold increase in volume. K) Correlation between pre-
treatment FDG in the canagliflozin group and the fold increase in volume. L) Correlation between 
the percent change in FDG uptake and the fold increase in volume from the beginning to the end 
of the therapeutic trial.
Table 1. Clinical characteristics of the patients with atypical adenomatous hyperplasia included in 
the study.
Pathology 
ID Age Sex
Smoking 
Status
Pack-
Years
Means of 
Detection 
Pathological 
Stage 
Overall 
Stage
S04-06316 58 M Current 40 Incidental T1aN0M0 IA
S07-06119 59 M Former 60 Symptomatic T3N0M0 IIB
S08-00530 54 F Never 0 Symptomatic TisN0M0 0
S10-02063 73 F
Former 31
Screening 
CXR T1aN0M0 IA
S11-00793 82 F Never 0 Incidental T1aN0M0 IA
S11-07781 75 F Former 20 Incidental T3N0M0 IIB
S11-16172
S12-04286 77 M T1bN0M0 IA
S13-07409 70 F Former 28 Surveillance T3N0M0 IIB
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